Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL\/min\/1.73 m2<\/sup> with no increase in AKI<\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n MONDAY, Nov. 30, 2020 (HealthDay News) — Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF) <30 mL\/min\/1.73 m2<\/sup>, according to a study published online Nov. 19 in the Clinical Journal of the American Society of Nephrology<\/em>.<\/p>\n George Bakris, M.D., from the University of Chicago Medicine, and colleagues conducted a post-hoc analysis to examine the impact of canagliflozin among CREDENCE trial participants with eGRF <30 mL\/min\/1.73 m2<\/sup> at randomization. Data were included for 174 of 4,401 participants (4 percent) with eGFR <30 mL\/min\/1.73 m2<\/sup>.<\/p>\n The researchers observed a 66 percent difference in the mean rate of eGFR decline from weeks 3 to 130 with canagliflozin versus placebo (mean slopes, \u00e2\u0080\u00931.30 versus \u00e2\u0080\u00933.83 mL\/min\/1.73 m2<\/sup>\/year). For those with <30 and \u00e2\u0089\u00a530 mL\/min\/1.73 m2<\/sup>, the effects of canagliflozin were consistent on kidney, cardiovascular, and mortality outcomes (all P interaction > 0.20). The estimate for kidney failure was similar for participants with eGFR <30 and \u00e2\u0089\u00a530 mL\/min\/1.73 m2<\/sup> (P interaction = 0.80). The rate of kidney-related adverse events or acute kidney injury associated with canagliflozin was not imbalanced between participants with eGFR <30 and \u00e2\u0089\u00a530 mL\/min\/1.73 m2<\/sup> (P interaction > 0.12).<\/p>\n “These results support the use and continuation of SGLT2 inhibitor treatment even in patients with eGFR <30 mL\/min\/1.73 m2<\/sup> until the commencement of maintenance dialysis or receipt of a kidney transplant, and clinicians should consider this when discussing treatment options for patients with low eGFR,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Janssen Research & Development, which sponsored the CREDENCE trial and developed canagliflozin in collaboration with Mitsubishi Tanabe Pharma Corporation.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n